Were the MIST CFO’s share sales discretionary or tax-related?

The reported sales of 58,007 and 12,245 common shares were made under sell-to-cover arrangements solely to satisfy income tax liabilities arising from vesting of PSUs and RSU awards, according to the Form 4 explanatory footnote.

Milestone Pharmaceuticals (MIST) CFO reports PSU vesting, option grant and tax-related share sales

Q: How many Milestone Pharmaceuticals (MIST) shares does the CFO hold after these transactions?

After the reported transactions, Amit Hasija directly held 99,848 common shares of Milestone Pharmaceuticals, plus 100,000 employee stock options and 60,300 restricted stock units , as disclosed in the Form 4 tables and footnotes.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Milestone Pharmaceuticals CFO & EVP of Corp. Development Amit Hasija reported multiple equity transactions. On December 12, 2025, he acquired 100,000 common shares from a performance stock unit award that vested when the FDA issued a New Drug Application approval letter for Cardamyst (etripamil), and received an option for 100,000 shares at an exercise price of $1.74.

On December 15, 2025, he sold 58,007 common shares at a weighted average price of $2.32 under a sell-to-cover arrangement for tax liabilities. On January 26, 2026, 20,100 restricted stock units converted into common shares and 12,245 of those shares were sold at a weighted average price of $1.93, also to cover taxes. After these transactions, he directly held 99,848 common shares, 100,000 stock options, and 60,300 restricted stock units.

Insider Trade Summary

Net Seller: 70,252 shares ($158,209)

Net Sell 6 txns

Insider Hasija Amit

Role CFO & EVP of Corp. Development

Sold 70,252 shs ($158K)

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	20,100	$0.00	--
Exercise	Common Shares	20,100	$0.00	--
Sale	Common Shares	12,245	$1.93	$24K
Sale	Common Shares	58,007	$2.32	$135K
Grant/Award	Employee Stock Option (right to buy)	100,000	$0.00	--
Grant/Award	Common Shares	100,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 60,300 shares (Direct); Common Shares — 112,093 shares (Direct); Employee Stock Option (right to buy) — 100,000 shares (Direct)

Footnotes (1)

Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil). Each PSU represents a contingent right to receive one common share. Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one common share. 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.

Form 4 Insider Transactions: What Each Field Means →

01/28/2026 - 06:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hasija Amit

(Last)

(First)

(Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL

H4M 2X6

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO & EVP of Corp. Development

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	12/12/2025		A		100,000⁽¹⁾	A	⁽²⁾	150,000	D
Common Shares	12/15/2025		S⁽³⁾		58,007	D	$2.32⁽⁴⁾	91,993	D
Common Shares	01/26/2026		M		20,100	A	⁽⁵⁾	112,093	D
Common Shares	01/26/2026		S⁽³⁾		12,245	D	$1.93⁽⁴⁾	99,848	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$1.74	12/12/2025		A		100,000		⁽⁶⁾	05/06/2034	Common Shares	100,000	$0	100,000	D
Restricted Stock Units	⁽⁵⁾	01/26/2026		M			20,100	⁽⁷⁾	⁽⁷⁾	Common Shares	20,100	$0	60,300	D

Explanation of Responses:

1. Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil).

2. Each PSU represents a contingent right to receive one common share.

3. Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively.

4. The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Each RSU represents a contingent right to receive one common share.

6. 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date.

7. One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Joseph Oliveto, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did MIST CFO Amit Hasija report in this Form 4?

Amit Hasija reported PSU vesting into 100,000 common shares, a grant of 100,000 stock options at $1.74, RSU vesting of 20,100 shares, and tax-related sales of 58,007 shares at $2.32 and 12,245 shares at $1.93.

How many Milestone Pharmaceuticals (MIST) shares does the CFO hold after these transactions?

After the reported transactions, Amit Hasija directly held 99,848 common shares of Milestone Pharmaceuticals, plus 100,000 employee stock options and 60,300 restricted stock units, as disclosed in the Form 4 tables and footnotes.

What triggered the 100,000 PSU vesting for the MIST CFO?

The 100,000 performance stock units vested when the Compensation Committee certified that the FDA issued a New Drug Application approval letter granting approval of Cardamyst (etripamil), as described in the Form 4 explanatory footnotes.

What are the terms of the 100,000 stock options granted to the MIST CFO?

The employee stock option covers 100,000 common shares at an exercise price of $1.74 per share. Half will vest on June 12, 2026 and half on December 12, 2026, if Amit Hasija continues providing service through each vesting date.

How do the MIST CFO’s restricted stock units vest over time?

One-fourth of the RSU award vests on each of January 26, 2026, January 26, 2027, January 26, 2028, and January 26, 2029, subject to Amit Hasija continuing to provide service through each respective vesting date.